1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
[.] shares (agg. up to ₹740 Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 952.48 | 696.69 | 601.76 |
| Total Income | 816.52 | 769.45 | 650.65 |
| Profit After Tax | 78.71 | 73.68 | 43.09 |
| EBITDA | 144.24 | 139.18 | 90.91 |
| NET Worth | 456.62 | 275.31 | 209.71 |
| Reserves and Surplus | 415.87 | 238.44 | 197.96 |
| Total Borrowing | 282.23 | 264.35 | 240.85 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹65.51 (+1.93%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹535.60 (-0.34%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,113.00 (+4.28%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,520.20 (-0.78%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹163.00 (-0.61%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.01 (-0.40%) |
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹138.70 (-0.18%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹38.13 (-4.65%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹185.00 (+0.00%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹273.75 (+0.09%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹255.30 (+2.51%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹112.00 (+1.82%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹254.50 (+1.13%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirement for capacity expansion at the Expansion Units | 360.00 |
| 2 | Prepayment of all or a portion of certain outstanding borrowings availed by our Company | 195.00 |
| 3 | General corporate purposes |
About Virupaksha Organics IPO
Incorporated in 1997, Virupaksha Organics is a research-driven Indian pharmaceutical company that makes active pharmaceutical ingredients (APIs), key starting materials (KSMs), and intermediates. Along with APIs and intermediates, it also provide contract development and manufacturing (CDMO) services to third-party pharma companies. As of March 31, 2025, the company offer 54 products (23 APIs and 31 intermediates) across a wide range of therapeutic areas such as anti-histamines, analgesics, anti-fungals, anti-diabetics, anti-depressants, anti-asthmatics, and more. It serve over 550 customers in more than 100 countries, including large multinational pharmaceutical companies in the US, Europe, and Japan. Many of its customer relationships span over eight years. The company have also filed 25 drug master files (DMFs) across global markets, including 11 with the USFDA. The operations are supported by six manufacturing units in Telangana and Karnataka with 223 reactors and a total capacity of 988 KL. The company uses advanced technologies such as flow chemistry, VapourTech reactors, infrared spectroscopy, NMR, mass spectrometry, and x-ray diffraction to maintain product quality and safe
Contact Details
Virupaksha Organics Ltd. AddressPlot No. B1 & B2, IDA Gandhinagar,Kukatpally, Medchal, MalkajgiriHyderabad, Telangana, 500037+ 91 4023075816cs@virupaksha.comVisit Website